CONSORT flowchart diagram of enrollment and randomization of subjects with cGVHD. Treatment consisted of oral belumosudil 200 mg daily and 200 mg twice daily in subjects with cGVHD. Randomization was stratified by cGVHD severity and prior exposure to ibrutinib. Reasons for discontinuation are shown in the following figure. Subjects were treated until clinically significant progression of cGVHD or unacceptable toxicity.